Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis
Abstract Sacubitril/valsartan is superior to enalapril in reducing the risks of cardiovascular death and preventing hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). However, patients often do not receive sacubitril/valsartan because of concerns about hypotension....
Guardado en:
Autores principales: | Hyoeun Kim, Jaewon Oh, Sanghyup Lee, Jaehyung Ha, Minjae Yoon, Kyeong-hyeon Chun, Chan Joo Lee, Sungha Park, Sang-Hak Lee, Seok-Min Kang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/aa72dddf037443319abf210345d1c0a0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparison of the Association Between Arterial Stiffness Indices and Heart Failure in Patients With High Cardiovascular Risk: A Retrospective Study
por: Chan Joo Lee, et al.
Publicado: (2021) -
Sacubitril/valsartan in real-life clinical practice
por: Yüksel Çavuşoğlu
Publicado: (2021) -
Sacubitril/valsartan alleviates myocardial fibrosis in diabetic cardiomyopathy rats
por: Jiao Ai, et al.
Publicado: (2021) -
Renal protective effect of sacubitril/valsartan in patients with heart failure
por: Hui-Ling Hsieh, et al.
Publicado: (2021) -
Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
por: Cuthbert JJ, et al.
Publicado: (2020)